KK
CRNX

KLP Kapitalforvaltning’s Crinetics Pharmaceuticals CRNX Stock Holding History

KLP Kapitalforvaltning’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$864K Buy
23,100
+3,400
+17% +$126K ﹤0.01% 1215
2026
Q1 		$716K Buy
19,700
+600
+3% +$26.8K ﹤0.01% 1218
2025
Q4 		$889K Buy
19,100
+300
+2% +$13.4K ﹤0.01% 1101
2025
Q3 		$783K Hold
18,800
– – ﹤0.01% 1169
2025
Q2 		$541K Buy
18,800
+2,800
+18% +$86.5K ﹤0.01% 1334
2025
Q1 		$537K Hold
16,000
– – ﹤0.01% 1257
2024
Q4 		$818K Buy
+16,000
New +$895K ﹤0.01% 1079

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KLP Kapitalforvaltning's CRNX Position: Q2 2026 in Review

KLP Kapitalforvaltning increased its Crinetics Pharmaceuticals (CRNX) stake by 17% in Q2 2026, buying an estimated $126K and bringing the position to 23,100 shares worth $864K. The position accounts for ﹤0.01% of the portfolio, ranked #1215.

KLP Kapitalforvaltning first reported a position in CRNX in Q4 2024 and has held it in 7 quarters since. The position peaked at $889K in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • KLP Kapitalforvaltning held 23,100 shares of Crinetics Pharmaceuticals worth $864K as of Q2 2026.
  • KLP Kapitalforvaltning bought 3,400 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $126K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of KLP Kapitalforvaltning's portfolio in Q2 2026, its #1215 holding.
  • KLP Kapitalforvaltning first reported a position in Crinetics Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • KLP Kapitalforvaltning's Crinetics Pharmaceuticals position peaked at $889K in Q4 2025.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q2 2026, filed 12 Aug 2026.